RDUS
Radius Health Inc.
Halal Rating :
Last Price
$12.72
Last updated:
Market Cap
-
7D Change
11.48%
1 Year Change
-50.68%
Company Overview
Industries
Exchange
Next Earnings Date
Note: Radius Health, Inc. (RDUS) was acquired by Gurnet Point Capital and Patient Square Capital in a transaction completed on July 12, 2022. The company was subsequently delisted from NASDAQ.
Prior to acquisition, Radius Health was a biopharmaceutical company focused on developing and commercializing endocrine therapeutics. Their main product was TYMLOS (abaloparatide), an FDA-approved treatment for postmenopausal women with osteoporosis at high risk for fracture.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Nov. 30, 2024 | $656.54m | $690.31m | - | $8.86m | 0.00% | 1.28% |
| Aug. 31, 2024 | $770.82m | $789.59m | - | $8.92m | 0.00% | 1.13% |
| May 31, 2024 | $673.92m | $917.07m | - | $7.37m | 0.00% | 0.80% |
Company Impact
Help us evaluate Radius Health Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.